Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Total Non-Current Liabilities: 2022-2023

Historic Total Non-Current Liabilities for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Dec 2023 value amounting to $50.9 million.

  • NewAmsterdam Pharma Co N.V's Total Non-Current Liabilities was N/A to $41.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $41.5 million, marking a year-over-year change of. This contributed to the annual value of $50.9 million for FY2023, which is 438793.20% up from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Total Non-Current Liabilities of $50.9 million as of FY2023, which was up 438,793.20% from $11,601 recorded in FY2022.
  • NewAmsterdam Pharma Co N.V's Total Non-Current Liabilities' 5-year high stood at $50.9 million during FY2023, with a 5-year trough of $11,601 in FY2022.
  • For the 2-year period, NewAmsterdam Pharma Co N.V's Total Non-Current Liabilities averaged around $25.5 million, with its median value being $25.5 million (2022).
  • Data for NewAmsterdam Pharma Co N.V's Total Non-Current Liabilities shows a peak YoY spiked of 438,793.20% (in 2023) over the last 5 years.
  • Yearly analysis of 2 years shows NewAmsterdam Pharma Co N.V's Total Non-Current Liabilities stood at $11,601 in 2022, then skyrocketed by 438,793.20% to $50.9 million in 2023.